Oral Management of Vitiligo

Introduction to Oral Therapies

• The British Association of Dermatologists explicitly states that oral dexamethasone cannot be recommended for arresting vitiligo progression due to unacceptable risk of side-effects (Grade B recommendation, Level 2++ evidence) 1, 2, 3
• Oral systemic therapies for vitiligo have extremely limited evidence and significant safety concerns, with low-dose oral corticosteroids may be considered only for actively spreading disease in carefully selected patients 1, 2

Primary Recommendation Against Oral Dexamethasone

• The British Association of Dermatologists recommends against the use of oral dexamethasone for vitiligo due to its unacceptable side-effects 1, 2, 3

Limited Role for Oral Corticosteroids

• For patients requiring systemic therapy, first exhaust topical options and phototherapy, then consider low-dose oral prednisolone for a maximum 4-month tapered course, monitoring closely for side effects, as per the British Journal of Dermatology guidelines 2, 4

Ginkgo Biloba Extract

• The British Association of Dermatologists suggests that Ginkgo biloba extract may be considered as an adjunctive option with minimal side effects, particularly for acrofacial vitiligo, based on a satisfactory randomized controlled trial 1, 3
• Ginkgo biloba has antioxidant and immunomodulatory properties, which may contribute to its potential benefits in vitiligo treatment 1, 3

Essential Pitfalls to Avoid

• The British Association of Dermatologists advises against prescribing oral corticosteroids for stable or slowly progressive vitiligo, as topical treatments and phototherapy remain first-line 2, 4

Baseline Assessment Before Oral Therapy

• Check thyroid function, including anti-thyroglobulin antibodies, before initiating any systemic treatment due to the high prevalence of autoimmune thyroid disease in vitiligo patients, as recommended by the British Journal of Dermatology 5, 4, 6
• Document disease extent with serial photographs every 2-3 months to objectively monitor response, as suggested by the British Journal of Dermatology 5, 4

Context: Why Oral Therapy Has Limited Role

• The evidence base for oral systemic treatments in vitiligo remains weak, with only one satisfactory RCT (Ginkgo biloba) identified in comprehensive guideline reviews, highlighting the need for further research 1, 3
• Topical immunosuppressants and phototherapy remain the evidence-based standard of care for vitiligo, with oral therapies rarely prescribed due to concerns about systemic side effects and unclear efficacy 2, 4